A Molecular Revolution Is Underway in Thoracic Oncology
Targetable alterations including BRAF V600E, EGFR exon 20 insertions, KRAS G12C mutations, MET exon 14 alterations, NTRK and RET rearrangements have taken up recent focus for investigators as data are pushing novel agents through the regulatory processes.
Targetable alterations in biomarkers such as BRAF V600E, EGFR exon 20 insertions, KRAS G12C, MET exon 14, NTRK and RET rearrangements have become the focus of recent translational research, driving the development of novel targeted agents and expanding the therapeutic landscape for non‑small‑cell lung cancer (NSCLC). Parallel advances in immunotherapy are opening opportunities to integrate checkpoint inhibition in early‑stage disease, while major clinical trials have begun to demonstrate the benefits of neoadjuvant and adjuvant regimens. The article reviews the evolution of precision oncology in lung cancer, highlighting recent FDA approvals, ongoing trials, and the role of comprehensive molecular testing, and discusses future directions in early‑stage management and prevention.
These biomarkers are the basis of precision treatment in lung cancer; identifying them allows the use of highly effective, mutation‑specific inhibitors and informs eligibility for immune‑based neoadjuvant or adjuvant strategies that may improve survival and cure rates.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT